WOODBURY EDWINA D sold $41K of NUS

WOODBURY EDWINA D sold 7,203 shares of NU SKIN ENTERPRISES, INC. (NUS) at $5.70 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WOODBURY EDWINA D
Published Jun 3, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NUS
Neutral
medium confidence
Mentioned
$NUS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUSNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling, but the 10b5-1 pre-arranged nature generally limits interpretability as new information.

02

Market read

A director’s 10b5-1 sale at $5.70 is unlikely to be a standalone fundamental catalyst, but can marginally influence sentiment/positioning.

03

What to watch

Traders may overreact to the headline sale size; the key is whether there are multiple consecutive insider sales or any concurrent fundamental disclosures (not present here).

Relevance 6/10Novelty 3/10Timing: Filed today; sale executed 2026-06-01 (10b5-1 plan).

Background

This is an SEC Form 4 insider transaction for Nu Skin Enterprises, Inc. (director sale) disclosed via EDGAR.

Company-level read

Ticker impact

$NUSNeutralMedium confidence
Context

Insider director WOODBURY EDWINA D filed an open-market sale of 7,203 shares of Nu Skin Enterprises at $5.70 on 2026-06-01.

Expected impact

Likely limited/short-lived price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 discloses the sale price/size and confirms a pre-arranged 10b5-1 plan, reducing the likelihood of new negative information.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • NU SKIN ENTERPRISES, INC.

    Subject of the Form 4 insider transaction; director sale disclosed.

  • WOODBURY EDWINA D

    Director who sold 7,203 shares under an open-market S transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NUSMed

Nu Skin (NUS) Q3 2026 Earnings Call Transcript

Nu Skin (NUS) reported Q3 2026 revenue of $311M, with adjusted EPS of $0.10. The company highlighted a 10% scan-to-purchase conversion rate and 3% year-to-date sales growth for LifePak. Nu Skin plans to launch innovations in anti-aging and women's health mid-2027 and is preparing for India's market entry in early 2027. The company is restructuring to improve efficiency and profitability, with a focus on East-West market alignment.

$NUSHigh

Nu Skin: Q3 Earnings Snapshot

Nu Skin Enterprises (NUS) reported a Q3 loss of $742,000, or 2 cents per share. Adjusted earnings were 10 cents per share. Revenue was $311 million. The company forecasts Q4 EPS of 11-21 cents and full-year EPS of 55-65 cents.

$NUSMed

Nu Skin Enterprises Q3FY26 Results: Revenue $311M, EPS $0.10

Nu Skin Enterprises reported Q3FY26 revenue of $311M and adjusted EPS of $0.10, within guidance. Full-year sales outlook lowered to $1.26B-$1.29B, below consensus. Gross margin declined to 65% from 70.5%. Q4 revenue expected at $310M-$340M, EPS at $0.11-$0.21. Company ranked No. 1 in beauty and wellness devices by Euromonitor.

$NUSMed

Nu Skin Enterprises Reports Third Quarter Earnings

NU SKIN ENTERPRISES, INC. (NUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Nu Skin Enterprises Reports Third Quarter Earnings PROVO, Utah — Nov. 5, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced third quarter revenue within its guidance range. Executive Summary Q3 2026 vs. Prior-year Quarter Revenue $311.0